|
|
Epidemiological studies of women under age 30
infected with human papillomavirus |
Zhihua LIU MD,Qing LI BM,Weihong LI BM, |
Cervical Disease Diagnosis
and Treatment of Maternal and Child Health Centers, Shenzhen Hospital,
Southern Medical University, Shenzhen 518028, China; |
|
|
Abstract The aim of this paper was to investigate the prevalence of human papilloma virus (HPV) infection in women under 30 years old with cervical intraepithelial neoplasia (CIN) or cervical cancer, in order to provide a basis for cervical cancer prevention and treatment. We recruited 2052 female cases from the education system in Futian District, Shenzhen city, from April 2006 to April 2008, with age ranging from 22 to 60 years old. Second-generation hybrid capture test was done for detection of female genital tract HPV and cervical colposcopy for screening CIN or cervical cancer. The prevalence of HPV and cervical precancerous lesions or cervical cancer was evaluated in different age groups of women. The HPV positive rate was 247/2052 (12.00%), and 35/2052 (1.71%) of the cases were≥CIN I by pathological diagnosis. In the 22―29-year-old age group, there were 291 cases, including 39HPV-positive cases (13.40%) and one case of pathological diagnosis≥CIN I (0.34%), and there were 1761 cases in the 30―60-year-old age group, including 208 HPV-positive cases (11.81%) and 34 cases of pathological diagnosis≥CIN I (1.93%). The HPV-positive rate of 22―29-year-old age group was higher than that of 30―60-year-old age group, but the difference was not significant (χ2 = 0.5967, P = 0.4398); the CIN and cervical cancer detection rate of the former group was lower than that of the latter one, and the difference was not significant either (χ2 = 3.7519, P = 0.0527). The cases in 30―60-year-old age group were divided into five age sub-groups, and the HPV-positive rate of the 22―29-year-old age group was compared with the remaining groups, and it was found that the HPV-positive rate of the former group (13.40%) was lower than that of the 40―44-year-old age group (14.70%) but higher than that of the other four groups. Moreover, the difference in the HPV-positive rate between the 22―29-year-old age group and the 50―60-year-old age group (6.06%) was significant (χ2 = 5.545, P = 0.018), but the difference between the 22― 29-year-old age group and each of the other four groups was not significant (P>0.05). In addition, the CIN and cervical cancer detection rate of the 22―29-year-old age group (0.34%) was lower than that of the remaining five groups, and the difference between the 22―29-year-old age group and the 35―39-year-old age group (2.26%), and between 22―29-year-old age group and 40―44-year-old age group (2.30%) was significant (χ2 = 4.446, P = 0.0035; χ2 = 4.525, P = 0.0363, respectively), but the difference between the 22―29-year-old age group and each of other three groups was not significant (P>0.05). Furthermore, 80.00% (28/35) cases of pathological diagnosis≥CIN I and 90.91% (10/11) lesions of pathological diagnosis≥CIN II occurred at 35―49 years of age. For many young women below the age of 30 who were infected with high-risk HPV were one-off infections, so it was not appropriate to recommend HPV detection as cervical precancerous lesions or cancer screening program for women less than 30 years old. The prevention and treatment of cervical cancer should be focused on those women more than 35 years of age.
|
Keywords
cervical cancer
human papilloma virus
cervical intraepithelial neoplasia
|
Issue Date: 05 December 2009
|
|
|
Parkin D M, Pisani P, Ferlay I. Global cancer statistics. CA Cancer J Clin, 1999, 49(1): 33–64
doi: 10.3322/canjclin.49.1.33
|
|
Li L D, Lu F Z, Zhang S W, Mu R, Sun X D, Huangpu X M, Sun J, Zhou Y S, Ouyang N H, Rao K Q, Chen Y D, Sun A M, Xue Z F, Xia Y. Themortality trend of malignant tumors in the past 20 years in Chinaand the recent prediction. Zhonghua ZhongLiu Za Zhi, 1997, 19(1): 3–9 (in Chinese)
|
|
Elliott P M, Tattersall M H, Coppleson M, Russell P, Coates A S, Solomon H J. Changing character of cervical cancer in young women. BMJ, 1989, 298(6685): 1451
doi: 10.1136/bmj.298.6685.1451
|
|
Wang Q J, Zhu W X, Xing X M, Li L. The Trend ofCancer Incidence in Urban Beijing from 1982 to 1997. Zhongguo Zhongliu, 2001, 10(9): 507–509 (in Chinese)
|
|
Woodman C B, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason T P, Young L S. Nature history of cervical human papillomavirus infectionin young women: a longitudinal cohorts study. Lancet, 2001, 357(9271): 1831–1836
doi: 10.1016/S0140-6736(00)04956-4
|
|
Richart R M. A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol, 1990, 75(1): 131–133
|
|
zur Hausen H. Condylomataacuminata and human genital cancer. CancerRes, 1976, 36(2 pt 2): 794
|
|
Belinson J, Qiao Y, Pretorius R, Zhang W, Keaton K, Elson P, Fischer C, Lorincz A, Zahniser D, Wilbur D, Pan Q, Li L, Biscotti C, Dawson A, Li A, Wu L, Ling Y, Ma C P, Yang X P. Prevalence of cervical cancer and feasibility of screening in ruralChina: a pilot study for the Shanxi Province Cervical Cancer ScreeningStudy. Int J Gynecol Cancer, 1999, 9(5): 411–417
doi: 10.1046/j.1525-1438.1999.99055.x
|
|
Franceschi S. TheIARC commitment to cancer prevention: the example of papillomavirusand cervical cancer. Recent Results CancerRes, 2005, 166: 277–297
doi: 10.1007/3-540-26980-0_18
|
|
Dai M, Bao Y P, Li N, Clifford G M, Vaccarella S, Snijders P J, Huang R D, Sun L X, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shanxi Province, people'sRepublic of China: a population-based study. Br J Cancer, 2006, 95(1): 96–101
doi: 10.1038/sj.bjc.6603208
|
|
Li L K, Dai M, Clifford G M, Yao W Q, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Qiao Y L, Franceschi S. Human papillomavirus infection in Shenyang City, people'sRepublic of China: A population-based study. Br J Cancer, 2006, 95(11): 1593–1597
doi: 10.1038/sj.bjc.6603450
|
|
Wu R F, Dai M, Qiao Y L, Clifford G M, Liu Z H, Arslan A, Li N, Shi J F, Snijders P J, Meijer C J, Franceschi S. Human papillomavirus infection in women in Shenzhen City,people's Republic of China, a population typical of recent Chineseurbanization. Int J Cancer, 2007, 121(6): 1306–1311
doi: 10.1002/ijc.22726
|
|
de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch F X. Worldwide prevalence and genotype distribution of cervicalhuman papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis, 2007, 7(7): 453–459
doi: 10.1016/S1473-3099(07)70158-5
|
|
Shi J F, Wu R F, Liu Z H, Zhou Q Z, Li N, Wu L N, Li Q, Wang Q, Liu B, Li R Z, Qiao Y L. Distribution of Human PapillomavirusTypes in Shenzhen Women. Zhongguo Yi XueKe Xue Yuan Xue Bao, 2006, 28(6): 832–836 (in Chinese)
|
|
Jin Y, Pan L Y. Role of high-risk human papillomavirustesting in the screening and management of cervical cancer precursors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2007, 29(5): 691–696 (in Chinese)
|
|
Frega A, Stentella P, De Ioris A, Piazze J J, Fambrini M, Marchionni M, Cosmi E V. Young women,cervical intraepithelial neoplasia and human papillomavirus: riskfactors for persistence and recurrence. Cancer Lett, 2003, 196(2): 127–134
doi: 10.1016/S0304-3835(03)00218-0
|
|
Rombaldi R L, Serafini E P, Villa L L, Vanni A C, Baréa F, Frassini R, Xavier M, Paesi S. Infection with human papillomavirusesof sexual partners of women having cervical intraepithelial neoplasia. Braz J Med Biol Res, 2006, 39(2): 177–187
doi: 10.1590/S0100-879X2006000200003
|
|
Gupta A, Arora R, Gupta S, Prusty B K, Kailash U, Batra S, Das B C. Human papillomavirusDNA in urine samples of women with or without cervical cancer andtheir male partners compared with simultaneously collected cervical/penilesmear or biopsy specimens. J Clin Virol, 2006, 37(3): 190–194
doi: 10.1016/j.jcv.2006.07.007
|
|
Bardin A, Vaccarella S, Clifford G M, Lissowska J, Rekosz M, Bobkiewicz P, Kupryjańczyk J, Krynicki R, Jonska-Gmyrek J, Danska-Bidzinska A, Snijders P J, Meijer C J, Zatonski W, Franceschi S. Human papillomavirus infectionin women with and without cervical cancer in Warsaw, Poland. Eur J Cancer, 2008, 44(4): 557–564
doi: 10.1016/j.ejca.2007.12.001
|
|
Bosch F X, Manos M M, Muñoz N, Sherman M, Jansen A M, Peto J, Schiffman M H, Moreno V, Kurman R, Shah K V. Prevalenceof human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 1995, 87(11): 796–802
doi: 10.1093/jnci/87.11.796
|
|
Dehn D, Torkko K C, Shroyer K R. Human papillomavirus testing and molecular markers ofcervical dysplasia and carcinoma. Cancer, 2007, 111(1): 1–7
doi: 10.1002/cncr.22425
|
|
Clifford G M, Gallus S, Herrero R, Muñoz N, Snijders P J, Vaccarella S, Anh P T, Ferreccio C, Hieu N T, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin H R, Sukvirach S, Thomas J O, Tunsakul S, Meijer C J, Franceschi S; IARC HPV Prevalence SurveysStudy Group. Worldwide distribution of human papillomavirus typesin cytologically normal women in the International Agency for Researchon Cancer HPV prevalence surveys: a pooled analysis. Lancet, 2005, 366(9490): 991–998
doi: 10.1016/S0140-6736(05)67069-9
|
|
Bell M C, Schmidt-Grimminger D, Patrick S, Ryschon T, Linz L, Chauhan S C. There is a high prevalence of human papillomavirus infectionin American Indian women of the Northern Plains. Gynecol Oncol, 2007, 107(2): 236–241
doi: 10.1016/j.ygyno.2007.06.007
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|